EUVIMEDEUVIMED entdecken
Crossref

The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045

Allini Mafra iD, Mathieu Laversanne iD, Rafael Marcos-Gragera iD, Humberto V S Chaves iD, Charlene Mcshane iD, Freddie Bray iD, Ariana Znaor iD

JNCI: Journal of the National Cancer Institute · 01.05.2025 · 117 (5) · 907-914

DOI: 10.1093/jnci/djae321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 10.12.2024. Verfasst von Allini Mafra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epidemiology and Prevention Group (EPI CAN), Department of Precision Health, Luxembourg Institute of Health, Strassen L-1445, Luxembourg. Hauptthemen laut MEDLINE: Multiple Myeloma, Global Health. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma (MM) is an important hematological malignancy in older adults, with a relatively poor prognosis. We aimed to present the current global patterns of incidence and mortality from MM, and predict new cancer cases and deaths by 2045.

Methods

Estimated numbers of MM cases and deaths and age-standardized (World) incidence and mortality rates per 100 000 people were obtained from the GLOBOCAN 2022 database covering 185 countries. Based on the incidence and mortality rates for 2022 and UN population estimates up to 2045, cases and deaths were predicted up to 2045.

Findings

Globally, 188 000 MM cases and 121 000 deaths were estimated in 2022. Eastern Asia and Northern America accounted for one-fifth of all cases each (21% and 19% respectively), followed by South-Central Asia (11%), and Western Europe (9%). The incidence rates were higher in men than in women with similar geographical patterns. While the incidence rates were highest in Northern America and Australia/New Zealand (≥4/100 000 for both sexes combined), the highest mortality rates (1.8/100 000) were found in Australia/New Zealand, Northern Europe, and Southern Africa. In the absence of changing rates, the estimated incidence and mortality of MM will increase by 71% and 79%, respectively by 2045 relative to 2022.

Interpretation

Our study highlights the substantial burden and variations in MM incidence and mortality reflecting global disparities in diagnosis and treatment. Improved surveillance and better disease control is needed to mitigate the global impact of MM in the presence of population aging and growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaGlobal HealthHumansIncidenceMaleFemaleAgedMiddle AgedMortalityAged, 80 and overAdult

Autor:innen und Institutionen

  • Cancer Epidemiology and Prevention Group (EPI CAN), Department of Precision Health, Luxembourg Institute of Health, Strassen L-1445, Luxembourg.
  • Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon 69007, France.
  • Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain.
  • Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Directorate Plan of Oncology, Girona 17004, Spain.
  • Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI-CERCA), Girona 17190 Salt, Spain.
  • Josep Carreras Leukaemia Research Institute, Girona 17004, Spain.

ORCID-Profile: Allini Mafra, Mathieu Laversanne, Rafael Marcos-Gragera, Humberto V S Chaves, Charlene Mcshane, Freddie Bray, Ariana Znaor

Förderung

  • World Health Organization

Zitieren

APA

Mafra, A., Laversanne, M., Marcos-Gragera, R., Chaves, H. V. S., Mcshane, C., Bray, F., & Znaor, A. (2025). The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. JNCI: Journal of the National Cancer Institute, 117(5), 907-914. https://doi.org/10.1093/jnci/djae321

Vancouver

Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F, et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. JNCI: Journal of the National Cancer Institute. 2025;117(5):907-914. doi:10.1093/jnci/djae321

BibTeX
@article{Mafra2025,
  author = {Mafra, Allini and Laversanne, Mathieu and Marcos-Gragera, Rafael and Chaves, Humberto V S and Mcshane, Charlene and Bray, Freddie and Znaor, Ariana},
  title = {The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  volume = {117},
  number = {5},
  pages = {907--914},
  doi = {10.1093/jnci/djae321}
}
Kostenlos starten →